Evidence map›Paper›PMID 27922933›Full record

ArticleMenopause (New York, N.Y.)2017

The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women.

Laura B Harrington, Marc Blondon, Mary Cushman, Andrew M Kaunitz, Jacques E Rossouw, Matthew A Allison, Lisa W Martin, Karen C Johnson, Jan Rosing, Nancy F Woods and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Menopause (New York, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 3 countries.

Laura B Harrington1Department of Epidemiology, University of Washington, Seattle, WA 2Department of Nutrition, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 3Division of Angiology and Haemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland 4Department of Medicine, University of Vermont, Burlington, VT 5Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL 6National Heart Lung and Blood Institute, Bethesda, MD 7Department of Preventive Medicine, University of California San Diego, San Diego, CA 8Department of Medicine, George Washington University, Washington, DC 9Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN 10Department of Biochemistry, Maastricht University, Maastricht, The Netherlands 11School of Nursing, University of Washington, Seattle, WA 12Department of Family Medicine and Public Health, University of California San Diego, San Diego, CA 13Department of Biostatistics, University of Washington, Seattle, WA.
Marc Blondon
Mary Cushman
Andrew M Kaunitz
Jacques E Rossouw
Matthew A Allison
Lisa W Martin
Karen C Johnson
Jan Rosing
Nancy F Woods
Andrea Z LaCroix
Susan R Heckbert
Barbara McKnight
Nicholas L Smith
University of Washington · USUniversity of California, San Diego · USGeorge Washington University · USHarvard University · USMaastricht University · NLNational Heart Lung and Blood Institute · USUniversity Hospital of Geneva · CHUniversity of Florida · USUniversity of Tennessee Health Science Center · USUniversity of Vermont · US

Funding

CVD Epidemiology Training Program in Behavior, the Environment and Global HealthT32HL098048 · NHLBI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Goodarz Danaei, ERIC B RIMM · 2009 to 2026
$6.9M
CVD Epidemiology Training ProgramT32HL007902 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M · 1998 to 2012
$3.6M
The Association of Vasomotor Symptoms with Thrombosis in Postmenopausal WomenR21HL121414 · NHLBI · UNIVERSITY OF WASHINGTON · PI SMITH, NICHOLAS L · 2014 to 2015
$184k
NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100003INHLBI NIH HHS HHSN268201100004INHLBI NIH HHS HHSN268201100046CNHLBI NIH HHS R21 HL121414NHLBI NIH HHS T32 HL007902NHLBI NIH HHS T32 HL098048NIA NIH HHS HHSN271201100004CWHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004C
6 · The paper itself

Abstract

objectiveVasomotor symptoms (VMS) may be a marker of cardiovascular risk. We aimed to evaluate the cross-sectional association of VMS presence and severity with hemostatic parameter levels measured at baseline among Women's Health Initiative (WHI) Hormone Therapy trial postmenopausal participants.

methodsThis cross-sectional analysis included 2,148 postmenopausal women with measures of VMS presence and severity reported in the 4 weeks before WHI baseline, who were not using warfarin or hormone therapy and for whom the following baseline hemostatic parameters were measured within the WHI Cardiovascular Disease Biomarker Case-Control Study: antithrombin, plasminogen activator inhibitor-1, protein C antigen, total and free protein S antigen, total and free tissue factor pathway inhibitor, D-dimer, normalized activated protein C sensitivity ratio, and thrombin generation. Using multiple linear regression, we estimated the adjusted average difference in each hemostatic parameter associated with VMS presence and severity. A multiple comparisons-corrected P value was computed using the P-min procedure to determine statistical significance of our smallest observed P value.

resultsWomen were 67 years of age on average and 33% reported VMS presence at baseline. There was some suggestion that VMS presence may be associated with a -0.34 adjusted difference in normalized activated protein C sensitivity ratio compared with no VMS (95% CI, -0.60 to -0.087; P = 0.009), but this association was not significant after correction for multiple comparisons (P = 0.073). VMS presence or severity was not significantly associated with the other hemostatic parameters.

conclusionsWe found no convincing evidence that VMS presence or severity was associated with levels of hemostatic parameters among postmenopausal women.

Indexed as

SweatingAgedAntigensAntithrombin ProteinsCross-Sectional StudiesFemaleFibrin Fibrinogen Degradation ProductsHemostasisHot FlashesHumansLipoproteinsMiddle AgedPlasminogen Activator Inhibitor 1PostmenopauseProtein CProtein SAntigensAntithrombin ProteinsFibrin Fibrinogen Degradation Productsfibrin fragment Dlipoprotein-associated coagulation inhibitorLipoproteinsPlasminogen Activator Inhibitor 1Protein CProtein SThrombin

Identifiers

PMID27922933
PMCPMC5365368
OpenAlexW2559783412

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.